Literature DB >> 30396301

What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

Gaia Giannone1,2, Andrea Milani3, Elena Geuna3, Danilo Galizia3, Federica Biello3, Filippo Montemurro3.   

Abstract

Entities:  

Keywords:  HER2; T-DM1; adjuvant; breast cancer; chemotherapy; lapatinib; metastatic; neratinib; pertuzumab; trastuzumab

Year:  2018        PMID： 30396301     DOI： 10.1080/14656566.2018.1543406

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  3 in total

1.  Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study.

Authors:  Elena Geuna; Pasquale Lombardi; Rossella Martinello; Davide Garino; Alessandro Bonzano; Danilo Galizia; Annamaria Nuzzo; Paola Berchialla; Paolo Becco; Monica Mangioni; Lorena De Zarlo; Filippo Montemurro
Journal:  Cancers (Basel)       Date:  2020-01-31       Impact factor: 6.639

2.  Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting.

Authors:  Salvatore Del Prete; Liliana Montella; Grazia Arpino; Giuseppe Buono; Carlo Buonerba; Pasquale Dolce; Olga Fiorentino; Maria Aliberti; Antonio Febbraro; Clementina Savastano; Giuseppe Colantuoni; Ferdinando Riccardi; Angela Ruggiero; Sabino De Placido; Michele Orditura
Journal:  Oncotarget       Date:  2020-06-02

3.  Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer.

Authors:  Mingli Han; Jianguo Hu; Pengwei Lu; Hui Cao; Chao Yu; Xiangke Li; Xueke Qian; Xue Yang; Yunqing Yang; Na Han; Dongwei Dou; Fan Zhang; Mulin Ye; Changcheng Yang; Yuanting Gu; Huaying Dong
Journal:  Cell Death Dis       Date:  2020-01-22       Impact factor: 8.469
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.